2022
DOI: 10.1101/2022.08.17.22278896
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Impact of the COVID-19 Pandemic on Personal Networks and Neurological Outcomes of People with Multiple Sclerosis: A Case-Control Cross-sectional and Longitudinal Analysis

Abstract: Background: The COVID–19 pandemic has negatively impacted the social fabric of people with multiple sclerosis (pwMS). Objective: To evaluate the associations between personal social network environment and neurological function in pwMS and controls during the COVID–19 pandemic and compare with the pre–pandemic baseline. Methods: We first analyzed data collected from 8 cohorts of pwMS and control participants during the COVID–19 pandemic (March–December 2020). We then leveraged data collected between 2017–20… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 35 publications
0
1
0
Order By: Relevance
“…This cross-sectional study included 368 participants (primary cohort) who enrolled in a clinicbased prospective cohort study (Prospective Investigation of Multiple Sclerosis in the Three Rivers Region, PROMOTE; Pittsburgh, PA) during 2017-2021 (Figure 1). [31][32][33][34][35][36][37][38][39][40][41][42] The cohort enrollment criteria included adults 18 years or older with a neurologist-confirmed diagnosis of MS according to the 2017 McDonald criteria. Given the clinical outcome of interest is relapse event indicative of inflammatory disease activity, we included pwMS of relapsing remitting (RRMS) and secondary progressive (SPMS) type and excluded primary progressive type (PPMS), which is not characterized by relapse events.…”
Section: Study Design Participants and Samplesmentioning
confidence: 99%
“…This cross-sectional study included 368 participants (primary cohort) who enrolled in a clinicbased prospective cohort study (Prospective Investigation of Multiple Sclerosis in the Three Rivers Region, PROMOTE; Pittsburgh, PA) during 2017-2021 (Figure 1). [31][32][33][34][35][36][37][38][39][40][41][42] The cohort enrollment criteria included adults 18 years or older with a neurologist-confirmed diagnosis of MS according to the 2017 McDonald criteria. Given the clinical outcome of interest is relapse event indicative of inflammatory disease activity, we included pwMS of relapsing remitting (RRMS) and secondary progressive (SPMS) type and excluded primary progressive type (PPMS), which is not characterized by relapse events.…”
Section: Study Design Participants and Samplesmentioning
confidence: 99%